Clinical and urodynamic evaluation in women with stress urinary incontinence treated by periurethral collagen injection by Martins, Sérgio Brasileiro et al.
695
Periurethral Collagen Injection Neurourology
International Braz J Urol Vol. 33 (5): 695-703, September - October, 2007
Clinical and Urodynamic Evaluation in Women with Stress
Urinary Incontinence Treated by Periurethral Collagen
Injection
S.B. Martins, E. Oliveira, R.A. Castro, M.G. Sartori, E.C. Baracat, G.R. Lima, M.J. Girao
Department of Gynecology, Federal University of Sao Paulo, UNIFESP, Sao Paulo, SP, Brazil
ABSTRACT
Objective: To evaluate the success of treatment with periurethral collagen injections in patients suffering from stress
urinary incontinence (SUI) with bladder neck hypermobility and intrinsic sphincter deficiency.
Materials and Methods: Forty women suffering from (SUI) were selected and divided into GI (consisting of 13 women with
SUI and bladder neck hypermobility) and GII (consisting of 27 women with SUI and intrinsic sphincter deficiency). Periure-
thral collagen was injected followed by a subjective evaluation (the need for urinary protectors) and an objective evaluation
through urodynamic study before and after the treatment.
Results: It was noticed that after 9 months there was a decrease in the need of urinary protectors in the two groups. It was
observed through the urodynamic study that either cure or improvement was achieved in 46% in GI and 40.7% in GII. There
was a significant increase in the leak pressure in GII. Moreover, there was a decrease in the volume of urine leak in the two
groups, being the results in GII statistically significant.
Conclusions: It was concluded that the periurethral collagen injection is useful for the treatment of the SUI. The results in
hypermobility are similar to those in intrinsic sphincter deficiency. In fact, it is a very simple out patient’s procedure, with
little side effects.
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INTRODUCTION
In its latest publication, the ICS (International
Continence Society) defines the urinary incontinence
as the complaint of any involuntary leakage of urine.
The stress urinary incontinence (SUI) is the complaint
of involuntary leakage on effort or exertion, or on
sneezing or coughing. It is the most common type of
urinary incontinence (1).
The stress urinary incontinence affects 10%
to 30% of women above 50 years of age. Patients
with intrinsic sphincter deficiency (ISD) present high
grade stress urinary incontinence and have low ab-
dominal leak point pressures on urodynamic studies.
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On the other hand, those with bladder neck
hypermobility present low grade stress urinary incon-
tinence (2).
Periurethral injection is being used for almost
one century for the treatment of stress urinary incon-
tinence. Several substances have been employed, and
among them Teflon, autologous fat, silicone micro-
implants, Durasphere, Zuidex and bovine collagen (2-
4). The injection aims at increasing urethral strength,
avoiding thus urinary leak.
Periurethral collagen injection (PCI) has been
used in the treatment of SUI due to intrinsic sphincter
deficiency since 1993 when it was first approved for
this application by the U.S. Food and Drug Adminis-
tration (5).
It has been reported that stress urinary in-
continence associated to intrinsic sphincter deficiency
can be treated with reasonable success by means of
periurethral collagen injections (6).
However, periurethral collagen injections
have also been efficacious in patients with bladder
neck hypermobility. The use of collagen in bladder
neck hypermobility was evaluated in a
nonrandomized prospective study that concluded that
this therapy is appropriate in those patients who wish
to avoid surgical risks and to whom surgery is ill ad-
vised (7).
Because collagen is less invasive than sur-
gery (i.e., retropubic bladder neck suspension or
slings), it could represent an interesting alternative for
the treatment of SUI. The side effects of collagen
injection are generally transient (e.g., urgency, fre-
quency syndrome, retention) (7,8).
Long-term outcomes for the most commer-
cially available bulking agents including collagen dem-
onstrate a cure rate of 25% to 45% and an improve-
ment rate of 25% to 70%. However, due to the de-
creased effectiveness of collagen with time, repeat-
ing injections may be necessary (9).
Most of the studies demonstrate that patient
selection is important in the outcomes with PCI. The
ideal patient should have diminished urethral function
with minimal proximal urethral hypermobility (10).
Thus, in the world literature there is no con-
sensus of opinion that patients with hypermobility will
not benefit from PCI.
We evaluated women with SUI with
hypermobility and intrinsic sphincter deficiency treated
with PCI through clinical criteria (number of urinary
protectors) and urodynamic parameters.
MATERIALS AND METHODS
Between January 2004 and January 2005 40
women with stress urinary incontinence were stud-
ied: 13 with bladder neck hipermobility (GI) and 27
with intrinsic sphincteric deficiency (GII).
All patients underwent a meticulous baseline
evaluation, including a complete history, physical ex-
amination and urine culture.
They also underwent a urodynamic evalua-
tion that confirmed the diagnosis of stress urinary in-
continence in both groups. The urodynamic evalua-
tion was repeated four months after the PCI.
In GII, the ISD was defined as an VLPP of
less than 60 cm H2O. Bladder neck displacement
greater than 10 mm measured by transperineal ultra-
sound was used to define bladder neck hipermobility
in GI.
The age ranged from 36 to 81 (mean of 60.4).
Age was homogeneous between GI and GII. The
groups were also homogeneous as to the number of
previous surgeries for stress urinary incontinence.
Women who presented contraindications to
collagen injections (allergic reaction) were excluded.
Subjects with neurogenic bladder, interstitial cystitis
and pelvic prolapse higher than stage II were also
excluded.
It was agreed that intraurethral collagen sub-
mucosal injection under local anesthesia (3 to 4 mL
xylocaine 1%) as an outpatient procedure would be
used for all patients. Collagen was injected at the 3-
o’clock, and 9-o’clock positions until coaptation of the
urethral mucosa was obtained (Figure-1). Sequential
injections were given 1 month apart until continence
was achieved or until it was predicted that further
injections would not provide success. Follow-up visits
were conducted at 1, 3, 4, 6 and 9 months after col-
lagen injection.
The success of the intervention was evalu-
ated by means subjective and objective criteria (num-
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ber of urinary protectors and urodynamic parameters
respectively).
Cure was defined as the absence of urine leak
during cistometry performed four months after col-
lagen periurethral injections, improvement when there
was urine leak with a volume 50% bigger than those
before treatment and we consider failure when the
urine leak occurred with a volume similar to that be-
fore PCI.
Figure 1 – Bladder neck before and after the periurethral injec-
tion of collagen.
The study was approved by the Medical Eth-
ics Committee of the Federal University of Sao Paulo,
Escola Paulista de Medicina. All patients gave in-
formed consent to participate in the study.
Statistical analysis was performed with the
software Analyze-it for Microsoft Excel. Statisti-
cal significance of differences among the number of
urinary protectors, Valsalva leak point pressure, maxi-
mum urethral closure pressure and volume of urine
leak before and after PCI were assessed using non-
parametric tests (Kruskal-Wallis or Mann-Whitney
tests, as appropriate). The occurrence of the cure,
improvement or failure was assessed using chi-square
test. P < 0.05 was considered statistically significant.
RESULTS
The need to use urinary protectors before
treatment in GI was smaller than GII. However, after
the treatment it was similar in the two groups (Figure-
2).
It was noticed that after 9 months there was
a significant decrease in the need to use urinary pro-
tectors in the two groups. (Figure-3).
It was observed through the urodynamic study
that either cure or improvement was achieved in 46%
in GI and 40.7% in GII (p > 0.05) (Table-1).
There was an increase in the leak pressure in
both groups, but it was significant only in GII (Graphic-
2). We also compared the maximum urethral closure
pressure (MUCP) in both groups before and after the
treatment with periurethral collagen injections and we
could not find significant differences (Figure-4).
Besides, there was a decrease in the volume
of leakage of urine during urodynamic evaluation in
the two groups, being the results in group II statisti-
cally significant (Figure-5).
In our series additional injections were given
in seven cases of GI and fifteen of GII (p > 0.05). As
for the volume of injection, there were no differences
between GI and GII.
As far as side effects are concerned, there
was no case of urinary retention. There was a case
of urinary infection in GI and another in GII, both were
successfully treated.
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Figure 2 – Number of urinary protectors before and after periurethral injections. Before (GI X GII): Kruskal-Wallis test (p < 0,05) ∴ GII
> GI. After - 1, 3, 6 and 9 months: (GI X GII): Kruskal-Wallis test (p > 0.05); 1, 3, 6 and 9 months: (GI X GI): Kruskal-Wallis test (p <
0.05); 1, 3, 6 and 9 months: (GII X GII): Kruskal-Wallis test (p < 0.05).
Figure 3 – Behavior of Valsalva leak point pressure before and after treatment with periurethral injection.GI: Kruskal-Wallis test: p >
0.05, GII: Kruskal-Wallis test: p < 0.05.
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COMMENTS
Collagen is a popular, safe and effective peri-
urethral bulking agent for the treatment of stress uri-
nary incontinence primarily due to intrinsic sphincter
deficiency.
Table 1 – Cystometric evaluation in the different groups.
Groups
GI
GII
Total
Cure
3
(23%)
3
(11.1%)
6
Improvement
3
(23%)
8
(29.6%)
11
Failure
7
(54%)
16
(59.3%)
23
Total
13
27
40
Outcome
χ² statistic = 1.0;  p = 0.6007.
The procedure may be done under local an-
esthesia, the period of convalescence is short, and
complications are minimal (11).
The reported success rate of collagen injec-
tion varies considerably according to patient selection
and follow-up duration and also according to the in-
Figure 4 – Behavior of maximum urethral closure pressure (MUCP) before and after treatment with periurethral injection.GI: Kruskal-
Wallis test: p > 0.05, GII: Kruskal-Wallis test: p > 0.05
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Figure 5 – Volume of leakage before and after treatment with periurethral injections. GI (Before X After): Anova – p > 0.05, GII (Before
X After): Anova – p < 0.05.
N Minimum    Maximum Mean S D
GI Before 13 100,00 400,00 188,4615 91,6375
After 10 100,00 300,00 190,0000 56,7646
GII Before 27 100,00 200,00 129,6296 46,5322
After 24 100,00 200,00 162,5000 49,4535
Descriptive Statistics:
vestigator definition of cure, improvement and fail-
ure.
There has been a previous collagen outcome
assessed by direct patient questioning on symptom
severity and pad requirements (12,13). The outcome
reported cure in 23% to 74% of cases, improvement
in 20% to 52% and failure in 6% to 33%.
Our results are similar from those concern-
ing the cure and improvement rates in the world lit-
erature. However, we believe that most cases re-
ported as cured in previous studies would be reclas-
sified as improved by our strict criteria. Moreover,
cure should imply the reestablishment of normal void-
ing patterns but in most studies cure denotes that the
patient no longer had stress urinary incontinence.
Thus, in most cases our new onset urge incontinence,
urinary urgency or difficult voiding may have been
present.
As opposed to these favorable long-term re-
sults, collagen injection is not considered to be a du-
rable procedure and most patients need additional treat-
ment sessions to achieve and maintain improvement
or cure. In our series in seven cases additional injec-
tions were given in GI and fifteen in GII (p > 0.05). In
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addition, there have not been differences of injection
volume between the two groups.
Our study observed a graduated increase of
the need of urinary protectors through consecutive
months after PCI (Graphic-1). This can be an evi-
dence of the low durability of this procedure.
We also observed urodynamic parameters
that have denoted that PCI can be useful in SUI with
intrinsic sphincter deficiency. In this group there was
a significant increase of the VLPP (Graphic-2). This
finding was also reported by other authors (14,15).
Overall the literature is inconclusive on the associa-
tion of improved incontinence grade and increased leak
point pressure after treatment as well as the predic-
tive nature of baseline leak point pressure (7).
Among some of the issues addressed in this
paper there are the value of collagen injections in pa-
tients with hypermobility and ISD. Regarding
hypermobility, ISD became the sole indication for the
use of collagen in patients with stress urinary inconti-
nence as a result of the US multicentric trial (16).
Since then a number of reports have demonstrated
the use of collagen in patients with hypermobility.
Herschorn & Radomski (17) found no difference in
outcomes with stress urinary incontinence with
hipermobility and ISD. The series of Moore et al. (18)
included patients with both types of SUI.
In the editorial by McGuire & Appell (6), the
results at more than 1 year in women with ISD were
statistically similar to those in women with
hypermobility, although Appell (19) subsequently re-
ported that the all patients with hypermobility required
bladder neck surgery with 2 years.
In our study, we found similar decrease in the
need to use urinary protectors in both groups. More-
over, cystometric evaluation allowed us to infer that
outcome results for hypermobility or ISD are similar.
Therefore, in the light of these several recent
studies, including our own, we concur that urethral
hypermobility is not a contraindication to injection
therapy.
CONCLUSIONS
In our series either cure or improvement was
achieved in 46% of the patients in GI and 40.7% in
GII. Therefore, periurethral collagen injection may
provide a minimally invasive means to treat both types
of stress urinary incontinence. We concur that blad-
der neck hypermobility is not a contraindication to in-
jection therapy.
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EDITORIAL COMMENT
The authors present their results of periure-
thral collagen injections in 27 women with stress uri-
nary incontinence.
Most studies to date have some urodynamic
outcomes included. Most are also of longer duration.
It is not clear from the introduction just what question
the authors want to address.
It is also not mentioned whether patients were
given additional injections. It is well known that
injectables, especially collagen, may require a few ini-
tial sessions for success. If this was not done, it may
have compromised the continence outcome.
Regarding the treatment outcomes, the dem-
onstrated leak on cystometry is understood, but there
are many patients who do not leak with catheters in
place. Do they possibly mean a cough-stress test as
an outcome measure? Furthermore, what do they
mean by volume of leakage? Is it volume in the blad-
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der at which the leakage occurred? If so, then they
should provide evidence that this test has been vali-
dated and standardized as an outcome measure.
It appears that the results of treatment in both
groups are similar, despite the pre-treatment testing,
and despite some discrepancies in urodynamic results.
In the Comments, the authors point to dis-
crepancies between their results and previously pub-
lished outcomes. From the data they present, the suc-
cess rates appear relatively similar. Longer term re-
sults are mostly less favorable than short-term results.
Furthermore, there are clinical outcome measures that
are valid in SUI studies. This study has no clinical
outcome measures, e.g. validated questionnaires,
against which to compare the urodynamic results.
The authors indicate the lack of durability as
evidenced by the increasing need for pads. They then
state that collagen can be useful in SUI with ISD.
However, they actually showed that the results in pa-
tients with normal sphincters (GII?) were the same.
Dr. Sender Herschorn
Sunnybrook and Women’s College
Health Sciences Center
Toronto, Ontario, Canada
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EDITORIAL COMMENT
This looks at 40 women suffering from stress
urinary incontinence over a one-year period. It is not
clear on what basis patients were differentiated into
the group with intrinsic sphincter deficiency and those
with normal sphincters – it is a very vague area and it
is difficult to separate out the groups. Clearly though
it is a consecutive series followed up prospectively –
the authors do not mention Zuidex, which is a new
agent, which has been around for some time now, and
this is an oversight in their literature survey.
Under results, it is interesting to see that there
is limited cure shown urodynamically.
Dr. Christopher R. Chapple
Department of Urology
Royal Hallashire Hospital
Sheffield, United Kingdom
E-mail: c.r.chapple@shef.ac.uk
